404 related articles for article (PubMed ID: 25393310)
21. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
22. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
[TBL] [Abstract][Full Text] [Related]
23. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
[TBL] [Abstract][Full Text] [Related]
24. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
25. Favorable prognostic value of SOCS2 and IGF-I in breast cancer.
Haffner MC; Petridou B; Peyrat JP; Révillion F; Müller-Holzner E; Daxenbichler G; Marth C; Doppler W
BMC Cancer; 2007 Jul; 7():136. PubMed ID: 17651480
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of Claudin family genes in colorectal cancer in a Chinese population.
Tang W; Dou T; Zhong M; Wu Z
Biofactors; 2011; 37(1):65-73. PubMed ID: 21294205
[TBL] [Abstract][Full Text] [Related]
28. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
[TBL] [Abstract][Full Text] [Related]
29. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
Piontek A; Eichner M; Zwanziger D; Beier LS; Protze J; Walther W; Theurer S; Schmid KW; Führer-Sakel D; Piontek J; Krause G
Mol Oncol; 2020 Feb; 14(2):261-276. PubMed ID: 31825142
[TBL] [Abstract][Full Text] [Related]
30. [Study of claudins and prognostic factors in some gastrointestinal diseases].
Gyorffy H
Magy Onkol; 2009 Dec; 53(4):377-83. PubMed ID: 20071310
[TBL] [Abstract][Full Text] [Related]
31. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
32. Expression and prognostic significance of ECT2 in invasive breast cancer.
Wang HK; Liang JF; Zheng HX; Xiao H
J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
[TBL] [Abstract][Full Text] [Related]
33. Role of transforming growth factor-β1 in triple negative breast cancer patients.
Zhang M; Wu J; Mao K; Deng H; Yang Y; Zhou E; Liu J
Int J Surg; 2017 Sep; 45():72-76. PubMed ID: 28754615
[TBL] [Abstract][Full Text] [Related]
34. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
35. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
[TBL] [Abstract][Full Text] [Related]
36. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
37. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
38. Novel genes associated with lymph node metastasis in triple negative breast cancer.
Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
[TBL] [Abstract][Full Text] [Related]
39. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
40. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
